Showing results (121-130 of 231) with videos related to

Sort By:
Pageof 24
Arthritis and Rheumatism|August 1, 2007
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosusKathleen McElhone, Janice Abbott, Joanna Shelmerdine, et al.
Annals of the Rheumatic Diseases|March 19, 2013
Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register--the EPIC-2-NOAR Study)Manjari Lahiri, Robert N Luben, Catharine Morgan, et al.
Cells|February 23, 2024
Novel Glycomimetics Protect against Glycated Low-Density Lipoprotein-Induced Vascular Calcification In Vitro via Attenuation of the RAGE/ERK/CREB PathwayGary P Sidgwick, Ria Weston, Ayman M Mahmoud, et al.
Clinical and Experimental Rheumatology|October 18, 2012
Treat-to-target in systemic lupus erythematosus: where are we today?Marta Mosca, Dimitrios T Boumpas, Ian N Bruce, et al.
The Journal of Rheumatology|September 3, 2010
The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosusKathleen McElhone, Madhura Castelino, Janice Abbott, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
ACR Open Rheumatology|July 26, 2026
Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control StudyZahi Touma, Ian N Bruce, Richard A Furie, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 21, 2022
Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus ErythematosusLucy M Carter, Adewonuola Alase, Zoe Wigston, et al.
Pageof 24